FMP
Silverback Therapeutics, Inc.
SBTX
NASDAQ
Inactive Equity
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
5.87 USD
0.06 (1.02%)
About
ceo
Dr. Peter A. Thompson M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.silverbacktx.com
exchange
NASDAQ
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
CIK
0001671858
ISIN
US82835W1080
CUSIP
82835W108
Address
500 Fairview Avenue North
Phone
206 456 2900
Country
US
Employee
90
IPO Date
Dec 3, 2020
Summary
CIK
0001671858
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
82835W108
ISIN
US82835W1080
Country
US
Price
5.87
Beta
0
Volume Avg.
171.41k
Market Cap
550.43M
Shares
-
52-Week
2.8-7.545
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
https://www.silverbacktx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SBTX News
It looks like there's no news available.
